Fax: (713) 794–4297
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia
Article first published online: 2 DEC 2011
DOI: 10.1002/cncr.26593
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Garg, R., Wierda, W., Ferrajoli, A., Abruzzo, L., Pierce, S., Lerner, S., Keating, M. and O'Brien, S. (2012), The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer, 118: 3531–3537. doi: 10.1002/cncr.26593
- †
Fax: (713) 794–4297
Publication History
- Issue published online: 2 JUL 2012
- Article first published online: 2 DEC 2011
- Manuscript Accepted: 11 JUL 2011
- Manuscript Revised: 2 JUN 2011
- Manuscript Received: 2 FEB 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- monoallelic;
- biallelic;
- 13q;
- chronic lymphocytic leukemia;
- prognostics
Abstract
BACKGROUND:
Fluorescence in situ hybridization can detect genomic abnormalities in up to 80% of cases and provides prognostic information on patients with chronic lymphocytic leukemia (CLL). Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis, there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q.
METHODS:
The authors reviewed the electronic database for patients with CLL who carried the 13q deletion as the sole abnormality and presented to The University of Texas MD Anderson Cancer Center (MDACC). Untreated patients were separated into 2 groups: those having monoallelic versus those with biallelic deletion of 13q. Using Mann-Whitney, chi-square, and Kaplan-Meier analysis, the baseline quantitative and qualitative variables for each group, along with the time from presentation to MDACC to treatment, were compared.
RESULTS:
A total of 176 patients were identified; 143 patients had a monoallelic deletion of 13q, whereas 33 patients had a biallelic deletion. The only significantly different values between the groups were albumin (4.5 g/dL vs 4.4 g/dL; P = .01) and zeta-chain-associated protein kinase 70 (ZAP70) expression (1.7% vs 4.8%; P = .010). The median time from fluorescence in situ hybridization analysis to treatment in both the monoallelic and biallelic groups had not been reached (P = not significant).
CONCLUSIONS:
Except for inconsequential differences in albumin and ZAP70 expression, there was no difference in the baseline characteristics between patients with CLL who had monoallelic or biallelic deletion of 13q. In addition, there was no significant difference in endpoints, including time to treatment. Cancer 2012;3531–3537. © 2011 American Cancer Society.